On now — join us online sciencesummitnyc.org/science-summ...

Happy to speak at this session on data, innovation, and the future of global health #UNGA80

So @petersinger.bsky.social and I just published a piece about the "$6 revolution" in generic GLP-1 drugs in Canada's @theglobeandmail.com. You can also read the original, longer version, on our Substacks. (see below) www.theglobeandmail.com/opinion/arti...

Happy to write this piece with @natashaloder.bsky.social. Canada is in a unique position as the only G7 country which will soon have no patent protections for GLP-1 drugs. The opportunities are humungous. Read more about what we think should happen www.theglobeandmail.com/gift/2be7b2e...

Happy to write this piece with @natashaloder.bsky.social. Canada is in a unique position as the only G7 country which will soon have no patent protections for GLP-1 drugs. The opportunities are humungous. Read more about what we think should happen www.theglobeandmail.com/gift/2be7b2e...

Canadians can benefit from tumbling prices on weight-loss drugs. Canada is in a unique position as the only G7 country where patent protection on semaglutide is about to lapse, by @petersinger.bsky.social @natashaloder.bsky.social www.theglobeandmail.com/opinion/arti... via @theglobeandmail.com

The WHO listing is a step in the right direction. But it’s only advice to governments. Its indications are also pretty conservative: diabetes w/ heart or kidney disease or w/ obesity. WHO could speed up availability by pre-qualifying GLP-1 manufacturers and updating its clinical guidelines. 2/n

Sept 5th: @who.int lists GLP-1 on Essential Medicines List. NVO and LLY shares drop. 🤷🏻‍♂️

Sept 5th: @who.int lists GLP-1 on Essential Medicines List. NVO and LLY shares drop. 🤷🏻‍♂️

Funding is also needed. @natashaloder.bsky.social & I outline several options for innovative finance for GLP-1 drugs and sketch the huge opportunity as the patent on semaglutide expires in many jurisdictions early next year. Check out our joint piece here: open.substack.com/pub/singerp/... 3/n

On Sept 5th, @who.int listed GLP-1 drugs on its Essential Medicines List. This listing covers about 75% of the 2.1 m lives saved per year in the lower estimate of the model David Brook and I developed. See the details on the screenshot below from our preprint: www.medrxiv.org/content/10.1... 1/n

GLP-1 drugs have been on the Medicines Patent Pool priority list for a while. Time for the companies to come forward now @who.int labeled them essential @thirugeneva.bsky.social @medicinespatentpool.org

Now this is an interesting idea.

On Sept 5th, @who.int listed GLP-1 drugs on its Essential Medicines List. This listing covers about 75% of the 2.1 m lives saved per year in the lower estimate of the model David Brook and I developed. See the details on the screenshot below from our preprint: www.medrxiv.org/content/10.1... 1/n

I was happy to participate in this @yalesph.bsky.social video about science and society

Tomorrow the WHO updates its essential medicines list—which over 150 countries adopt as policy. Will GLP-1 drugs be on the list? Read my article with @petersinger.bsky.social which explains why such a shift could be an important next step overmatter.substack.com/p/the-6-revo...

Good reads at singerp.substack.com

Details from @natashaloder.bsky.social and @petersinger.bsky.social overmatter.substack.com/p/the-6-revo...

5/ The World Health Organization needs to step up. GLP-1 drugs deserve inclusion in global obesity strategies. Delay could mean hundreds of thousands of preventable deaths.

1️⃣ Earlier this month, the US health department—headed by RFK Jr.—terminated $500m contracts supposedly related to mRNA vaccines for respiratory viruses. Debunked safety concerns were cited as the reason. But far more than this was cut. #Science #Vaccines #HealthPolicy #RNA #mRNA

@natashaloder.bsky.social and I argue that company foundations should be able to promote global access — by supporting financial innovations or research— on products their related companies make in cases of massive public benefits. See our substack at singerp.substack.com & overmatter.substack.com

In 5 months, semaglutide (Ozempic) goes off patent in parts of the world. Manufacturing cost is about $6/month. India, China, Brazil, and Canada will get generics. The US, UK, and Europe won't. Yet. Eventually, this will be dirt cheap for everyone. That's how obesity ends.

❗️

3/ This isn’t just about weight loss. These drugs could save up to 3.1M lives per year, as per @petersinger.bsky.social and help with diabetes, improve heart health, and may also impact addiction and dementia risk.

mRNA vaccines can be quickly programmed based on viral genomic sequence. It’s like anti-viral software updates IRL. That quick and nimble nature is what makes them so useful.

2/ Over 1B people worldwide suffer from obesity. Indian manufacturers are ready to scale production for less than $6/month. Massive accessibility incoming.

1/ 🚨 The $6 revolution: Generic semaglutide—the weight loss drug—will soon be available in countries like India, China, Brazil, and Canada as the patent expires.

mRNA vaccines can be quickly programmed based on viral genomic sequence. It’s like anti-viral software updates IRL. That quick and nimble nature is what makes them so useful.

Must read - overmatter.substack.com/p/the-6-revo...

6/ As @petersinger.bsky.social and I write in our new Substack, we stand on the brink of a new era in public health—if we’re bold enough to seize it. #HealthTech #Obesity #Semaglutide #GlobalHealth overmatter.substack.com/p/the-6-revo...

🔥🧵👇🏻‼️

🔥🧵👇🏻‼️

@natashaloder.bsky.social and me on the potential GLP-1 revolution in global health. More open.substack.com/pub/singerp/...

In the face of massive shifts underway, what is the future of global health? In this recent piece, I argue it’s innovation — in products and services, finance, and trust. Read more … open.substack.com/pub/singerp/...

The arrival of generic semaglutide is a huge opportunity for global public health. In a piece co-written with @natashaloder.bsky.social, we explain further. open.substack.com/pub/singerp/...

What could the world do if weight-loss drugs were cheap? We are about to find out. A new piece by @natashaloder.bsky.social and myself on Subtack. open.substack.com/pub/singerp/...

What could the world do if weight-loss drugs were cheap? We are about to find out. A new piece by @natashaloder.bsky.social and myself on Subtack. open.substack.com/pub/singerp/...

What could the world do if weight-loss drugs were cheap? We are about to find out. A new piece by @petersinger.bsky.social and myself on Subtack.

"Global health is dead. Long live global health." Peter Singer, MPH '90, joined Prof. Zack Cooper for a panel discussion on the cost of and connection to the health ecosystem during our Alumni Day earlier this summer. After the panel, he took a moment to share his biggest takeaways with us. 1/3

The Economist's @natashaloder.bsky.social and @petersinger.bsky.social on generic semaglutide. How generic weight loss drugs could save millions of lives. open.substack.com/pub/overmatt...

The arrival of generic semaglutide from 2025 is a huge opportunity for global public health. In a piece co-written with @petersinger.bsky.social, we explain further. open.substack.com/pub/overmatt...

The arrival of generic semaglutide is a huge opportunity for global public health. In a piece co-written with @natashaloder.bsky.social, we explain further. open.substack.com/pub/singerp/...

Global access to GLP-1 drugs could save 2.1-3.1 million lives a year. www.medrxiv.org/content/10.1...

🆕 Just published; our updated estimate on lives saved with global access to GLP-1 drugs. We estimate the annual number of lives saved is 2.1 million (for people with T2DM or obesity with CVD) to 3.1 million (for people with T2DM or obesity with/without CVD). www.medrxiv.org/content/10.1...

🆕 Just published; our updated estimate on lives saved with global access to GLP-1 drugs. We estimate the annual number of lives saved is 2.1 million (for people with T2DM or obesity with CVD) to 3.1 million (for people with T2DM or obesity with/without CVD). www.medrxiv.org/content/10.1...

Check out my new post on #UN80 reform. Successful UN reform requires relentless focus on results. I describe results-based tools developed at WHO that are easily adaptable to the UN system. The tools are available. But is the leadership and governance? open.substack.com/pub/singerp/...

Check out my new post on #UN80 reform. Successful UN reform requires relentless focus on results. I describe results-based tools developed at WHO that are easily adaptable to the UN system. The tools are available. But is the leadership and governance? open.substack.com/pub/singerp/...

David Nabarro dedicated his life to global public good. He was hyper intelligent, thoughtful, articulate, approachable. Sad to hear of his death. I considered him a friend. May he RIP.